A New Psychosocial Tool for Gaining Patient Understanding and Acceptance of Long-acting Injectable Antipsychotic Therapy

by Robert A. Lasser, MD, MBA; Nina R. Schooler, PhD; Mary Kujawa, MD, PhD;
Kathleen Jarboe, PHMCNS-BC; John Docherty, MD; and Peter Weiden, MD

Dr. Lasser is with Shire Pharmaceuticals (Dr. Lasser was with Johnson & Johnson at the time of the development of this manuscript); Dr. Schooler is with SUNY Downstate Medical Center, Brooklyn, New York; Dr. Kujawa is with Hoffman-La Roche, Nutley, New Jersey (Dr. Kujawa was with Ortho-McNeil Janssen Pharmaceutical Affairs, LLC, at the time of the development of this manuscript); K. Jarboe is with Quintiles, Inc., Atlanta, Georgia; Dr. Docherty is with Joan and Sanford I. Weill Medical College of Cornell University, New York, New York; and Dr. Weiden is with the University of Illinois, Chicago, Illinois.